Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues.
about
Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases.Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations."Cocktail" approaches and strategies in drug development: valuable tool or flawed science?Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned?Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjectsEffects of lasofoxifene on the pharmacokinetics and pharmacodynamics of single-dose warfarin.Strategies to assess the drug interaction potential in translational medicine.Population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures?Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check.Nonnucleoside reverse transcriptase inhibitor pharmacokinetics in a large unselected cohort of HIV-infected women.Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women.Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease.So many studies, too few subjects: establishing functional relevance of genetic polymorphisms on pharmacokinetics.The Utility of a Population Approach in Drug-Drug Interaction Assessments: A Simulation Evaluation.FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling.
P2860
Q31900846-977B2A6B-58F2-4532-8CA7-927B3F93F669Q35009679-8CB480AD-585F-4304-AC6C-EC8579EE183AQ35640730-49DEFA0C-A3A4-49A5-B180-DF8D64A3D1FCQ35774851-1CFBDAA8-337E-41BF-A7EF-0B08DBEA875DQ35826093-5CC4D81F-2920-4092-8A52-26A54FBB57D0Q35827687-E2FA2744-D805-4699-8EC2-EA6962A493AEQ36609743-96B4C491-0A28-4DAA-8579-DD45C366DC29Q36628026-D3117985-250B-4416-9AEA-755F7ED275F1Q36927353-F230F223-4E8D-495D-A9F1-DB0730079A9BQ37237006-84C87E8A-94A4-4D6F-BC31-AAED5B39B3ABQ37641171-9B7669F3-9D9F-4CC8-A9B0-AD9B1BB71381Q38287050-8DA22AE6-E409-4360-B4FF-9F96C085AF38Q40349386-9D2D4927-FAF3-4F3A-B080-077F2967AAE0Q50641094-AAA7AF88-3F32-4115-BF86-6CE06C32F5F1Q52205708-F0E89A53-F820-4D03-ACAD-E0BBE42A582B
P2860
Assessment of the quality and quantity of drug-drug interaction studies in recent NDA submissions: study design and data analysis issues.
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Assessment of the quality and ...... sign and data analysis issues.
@ast
Assessment of the quality and ...... sign and data analysis issues.
@en
type
label
Assessment of the quality and ...... sign and data analysis issues.
@ast
Assessment of the quality and ...... sign and data analysis issues.
@en
prefLabel
Assessment of the quality and ...... sign and data analysis issues.
@ast
Assessment of the quality and ...... sign and data analysis issues.
@en
P2093
P2860
P1476
Assessment of the quality and ...... sign and data analysis issues.
@en
P2093
P2860
P304
P356
10.1177/00912709922011764
P577
1999-10-01T00:00:00Z